RLMD stock forecast, quote, news & analysis
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone... Show more
Why Relmada Therapeutics (RLMD) Stock Is Up +22.7% in the Last 30 Days
Key Takeaways
- Relmada Therapeutics (RLMD) rose roughly 22.7% over the last 30 days, climbing from a $3.48 close on October 5, 2026, to a $4.27 close on November 3, 2026.
- The advance marked a rebound from a mid-October low near $3.10, which followed a broader multi-month pullback in the stock.
- The company announced its third-quarter 2026 results date (November 12) and plans to present at the Jefferies Global Healthcare Conference, events that coincided with the latest leg higher.
- Insider purchases by the chief executive officer and chief financial officer, along with a reiterated Buy rating and $19.00 price target from Mizuho Securities, underscored ongoing institutional attention.
- Even with the 30-day gain, RLMD remains down roughly 19% over the trailing three months, reflecting continued repricing of its clinical pipeline.
- You can access more detailed Price Targets, Earnings, and Forecast data on Tickeron's dedicated pages.
- Explore Trending AI Robots to see how algorithmic strategies are currently positioned across the market.
Relmada Therapeutics (RLMD) Company Overview and Market Position
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company headquartered in Coral Gables, Florida, advancing therapies for oncology and central nervous system (CNS) disorders. Its lead oncology candidate, NDV-01, is an intravesical formulation of gemcitabine and docetaxel being developed for non-muscle invasive bladder cancer (NMIBC). The company's CNS pipeline is anchored by sepranolone, a GABA-A modulating steroid antagonist acquired from Asarina Pharma in early 2025 and studied for Tourette syndrome, Prader-Willi syndrome, and other compulsivity-related disorders.
Relmada repositioned its pipeline after discontinuing its former lead program, the NMDA receptor antagonist REL-1017 (esmethadone), which missed primary endpoints in multiple Phase 3 depression trials. Investors now follow RLMD primarily for its oncology and rare-disease programs, its regulatory timeline toward investigational new drug (IND) filings, and a cash position strengthened by a $160 million private placement completed in March 2026.
Relmada Therapeutics (RLMD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RLMD gained approximately 22.7%, rising from a closing price of $3.48 on October 5, 2026, to $4.27 on November 3, 2026. The move was not linear: shares slid toward $3.10 in mid-October before staging a sharp two-week recovery that accelerated in early November.
The longer-term picture remains mixed. Over the trailing three months, RLMD is down roughly 19%, having traded near $5.30 in early August before a sustained pullback. The pattern highlights a stock that has stabilized and rebounded off its autumn lows even as it remains well below late-summer levels.
What Drove RLMD Stock Price in the Last 30 Days
Several verified developments supported the recovery. In early September, Relmada's chief executive officer and chief financial officer disclosed combined open-market purchases of approximately 200,000 shares, a signal of management confidence that coincided with renewed attention on the name. Mizuho Securities analyst Uy Ear reiterated a Buy rating and a $19.00 price target on the stock, well above its recent trading range.
The sharpest leg of the rally arrived in early November. On November 3, 2026, the company announced it would report third-quarter 2026 financial results on November 12, 2026, and separately disclosed plans to participate in the Jefferies Global Healthcare Conference in London. Anticipation ahead of these events, together with the company's stated goal of filing INDs for NDV-01 and sepranolone before the end of 2026, contributed to a more constructive tone after weeks of selling pressure.
What Drove RLMD Stock Performance Over the Last Quarter
The trailing three-month decline traces back to Relmada's second-quarter 2026 results reported in early August. The company posted a narrower-than-expected loss per share, but shares sold off in the following sessions as investors weighed execution risk and the timeline for advancing its clinical programs. The September departure of the company's chief medical officer for urology added further turnover-related uncertainty.
Broader dynamics also played a role. Small-cap and pre-revenue biotechnology names remained sensitive to risk appetite, and the earlier $160 million financing at $4.75 per share introduced a dilution overhang that lingered over the stock. The subsequent recovery suggests investors have begun refocusing on near-term catalysts—including the planned IND filings and the resumption of registrational planning for NDV-01—rather than the financing's dilutive effect.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading bots drawn from a broader universe of hundreds of AI-driven strategies that trade thousands of tickers. Only the top-performing and most relevant bots appear in this section, and each differs in strategy, holding period, and performance metrics, allowing users to compare momentum, swing, and trend-following models side by side. The page is designed to help traders identify strategies that have demonstrated strength under current market conditions. Those interested in data-driven approaches can review the featured robots to see how automation is being applied across the market.
RLMD Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term event is Relmada's third-quarter 2026 earnings report scheduled for November 12, 2026, when management is expected to update its cash position and clinical timelines. Investors will also monitor progress toward year-end IND filings for both NDV-01 and sepranolone, as well as any updates on the Phase 3 RESCUE registrational program for NDV-01 in intermediate-risk NMIBC.
Key risks include execution on GMP manufacturing for NDV-01, regulatory feedback, competition in the bladder-cancer and CNS spaces, and the financing needs typical of clinical-stage biotechnology companies. As with all development-stage biotechs, the stock's direction will likely remain tied to data readouts, regulatory milestones, and broader risk sentiment in the small-cap biotech sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RLMD in upward trend: price rose above 50-day moving average on November 06, 2026
RLMD moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on RLMD as a result. In 76 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for RLMD just turned positive on October 20, 2026. Looking at past instances where RLMD's MACD turned positive, the stock continued to rise in 30 of 38 cases over the following month. The odds of a continued upward trend are 79%.
The 10-day moving average for RLMD crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLMD advanced for three days, in 226 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for RLMD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 24 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RLMD broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RLMD entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.014) is normal, around the industry mean (3.498). P/E Ratio (-4.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. RLMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases
Industry Biotechnology